Amedeo Smart

Free Medical Literature Service



Ovarian Neoplasms

  Free Subscription


1 Ann Oncol
2 Cancer
2 Curr Treat Options Oncol
1 Discov Oncol
4 Gynecol Oncol
1 Int J Gynaecol Obstet
1 Int J Oncol
1 J Clin Oncol
1 Oncogene
1 Oncol Rep
1 Oncology (Williston Park)
2 PLoS One

    Ann Oncol

  1. LEDERMANN JA, Matias-Guiu X, Amant F, Concin N, et al
    ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease.
    Ann Oncol. 2024 Jan 29:S0923-7534(23)05103-7. doi: 10.1016/j.annonc.2023.
    >> Share


  2. MUTCH D, Voulgari A, Chen XM, Bradley WH, et al
    Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti-PD-L1, for BRCA wild-type, platinum-sensitive, recurrent ovarian cancer.
    Cancer. 2024 Jan 30. doi: 10.1002/cncr.35222.
    >> Share

  3. BYRD DA, Zouiouich S, Karwa S, Li XS, et al
    Associations of serum trimethylamine N-oxide and its precursors with colorectal cancer risk in the Prostate, Lung, Colorectal, Ovarian Cancer Screening Trial Cohort.
    Cancer. 2024 Jan 29. doi: 10.1002/cncr.35219.
    >> Share

    Curr Treat Options Oncol

  4. RATNAPARKHI R, Javellana M, Jewell A, Spoozak L, et al
    Evaluation of Homologous Recombination Deficiency in Ovarian Cancer.
    Curr Treat Options Oncol. 2024 Feb 1. doi: 10.1007/s11864-024-01176.
    >> Share

  5. ANASTASIO MK, Shuey S, Davidson BA
    Antibody-Drug Conjugates in Gynecologic Cancers.
    Curr Treat Options Oncol. 2024;25:1-19.
    >> Share

    Discov Oncol

  6. CAO M, Xiao L, Chen S, Huang J, et al
    Characterization of hypoxia-responsive states in ovarian cancer to identify hot tumors and aid adjuvant therapy.
    Discov Oncol. 2024;15:23.
    >> Share

    Gynecol Oncol

  7. TUBRIDY EA, Eiva MA, Liu F, Omran DK, et al
    CD137+ tumor infiltrating lymphocytes predicts ovarian cancer survival.
    Gynecol Oncol. 2024;184:74-82.
    >> Share

  8. WEHN AK, Qiu P, Lunceford J, Yarunin A, et al
    Concordance between an FDA-approved companion diagnostic and an alternative assay kit for assessing homologous recombination deficiency in ovarian cancer.
    Gynecol Oncol. 2024;184:67-73.
    >> Share

  9. MOFFAT GT, Kong W, MacKay HJ, McGee J, et al
    Real-world outcomes associated with bevacizumab combined with chemotherapy in platinum-resistant ovarian Cancer.
    Gynecol Oncol. 2024;184:51-56.
    >> Share

  10. MUSACCHIO L, Palluzzi E, Di Napoli M, Lauria R, et al
    Real world data of niraparib in platinum sensitive relapsed ovarian cancer: A multicenter experience of the MITO group.
    Gynecol Oncol. 2024;184:24-30.
    >> Share

    Int J Gynaecol Obstet

  11. BRENT SE, McGee J, Vicus D, Kim R, et al
    Rates of genetic consultation in high-grade serous ovarian cancer patients in the era of PARP inhibitor therapy: A population-based study.
    Int J Gynaecol Obstet. 2024 Jan 29. doi: 10.1002/ijgo.15391.
    >> Share

    Int J Oncol

  12. GENG D, Zhou Y, Wang M
    Advances in the role of GPX3 in ovarian cancer (Review).
    Int J Oncol. 2024;64:31.
    >> Share

    J Clin Oncol

  13. PAVLIK EJ, van Nagell JR Jr, Dietrich CS 3rd, Ueland FR, et al
    Compelling Story of Ovarian Cancer Screening.
    J Clin Oncol. 2024 Feb 2:JCO2302424. doi: 10.1200/JCO.23.02424.
    >> Share


  14. WU J, Wu Y, Chen S, Guo Q, et al
    PARP1-stabilised FOXQ1 promotes ovarian cancer progression by activating the LAMB3/WNT/beta-catenin signalling pathway.
    Oncogene. 2024 Jan 31. doi: 10.1038/s41388-024-02943.
    >> Share

    Oncol Rep

  15. HOU Y, Zhao X, Nie X
    Enhancing the therapeutic efficacy of NK cells in the treatment of ovarian cancer (Review).
    Oncol Rep. 2024;51:50.
    >> Share

    Oncology (Williston Park)

  16. LA SPINA S, Scollo P, Pecorino B, Lombardo V, et al
    Life Experience of Survivors of Gynecologic Cancers: A Survey Conducted in Italy.
    Oncology (Williston Park). 2024;38:15-19.
    >> Share

    PLoS One

  17. Expression of Concern: Minocycline Suppresses Interleukine-6, Its Receptor System and Signaling Pathways and Impairs Migration, Invasion and Adhesion Capacity of Ovarian Cancer Cells: In Vitro and In Vivo Studies.
    PLoS One. 2024;19:e0298444.
    >> Share

  18. YONG CM, Yehgambaram PAP, Lee SWH
    Cost-effectiveness analysis of olaparib maintenance therapy for BRCA mutation ovarian cancer in the public sector in Malaysia.
    PLoS One. 2024;19:e0298130.
    >> Share

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016